Acute myeloid leukemia trials in Italy

In Italy 61 Also abroad 761

61 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Not yet taking people in Italy
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Where
Bologna, Ravenna
Age
18 years and over
People
126 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07929740 · EU 2025-524332-19-00
Phase 3Taking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Ancona, Bergamo, Castelfranco Veneto, Florence, Genoa, Milan, Palermo, Perugia, Pescara, Ravenna, Rome, San Giovanni Rotondo
Age
18 years and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
Phase 1Taking people
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Where
Bergamo, Pisa, Rozzano
Age
18 years and over
People
78 worldwide
Run by
Genmab
See details and how to joinNCT07384715 · EU 2025-523101-15-00
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Bergamo, Bologna, Brescia, Meldola, Milan, Pavia, Perugia, Pesaro, Ravenna, Reggio Calabria, Rozzano, San Giovanni Rotondo, Torino
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
No phaseTaking people
The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial
Where
Bari, Roma, Verona
Age
18 years to 75 years
People
75
Run by
Gruppo Italiano Malattie EMatologiche dell'Adulto
See details and how to joinNCT07912684
Phase 3Taking people
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Where
Alessandria, Ascoli Piceno, Brindisi, Florence, Lecce, Milan, Monza, Pavia, Pesaro, Reggio Calabria, Roma, San Giovanni Rotondo
Age
18 years to 75 years
People
366 worldwide
Run by
Priothera SAS
See details and how to joinNCT05429632
Phase 3Taking people
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Where
Roma, Vicenza
Age
18 years to 71 years
People
150 worldwide
Run by
Quetzal Therapeutics
See details and how to joinNCT07504458 · EU 2025-524810-28-00
No phaseTaking people
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Where
Ancona, Bologna, Brescia, Brindisi, Busto Arsizio, Castelfranco Veneto, Como, Cremona, Cuneo, Ferrara, Florence, Genova, Meldola, Milan, Naples, Novara, Padova, Palermo, Perugia, Pescara, Ravenna, Rimini, Roma, Salerno, Torino, Vicenza
Age
6 years and over
People
4,000 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024
Phase 3Taking people
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Where
Ancona, Bologna, Brescia, Busto Arsizio, Castelfranco Veneto, Florence, Genoa, Meldola, Milan, Naples, Padova, Palermo, Pavia, Perugia, Pescara, Piacenza, Ravenna, Rimini, Rome, San Giovanni Rotondo, Siena, Turin, Vicenza
Age
18 years and over
People
339 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06713837 · EU 2024-514517-35-00
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Bologna, Ravenna
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 3Taking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Bologna, Milan, Rome, Turin
Age
18 years and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Alexandria, Bari, Bergamo, Bologna, Brescia, Candiolo, Florence, Genoa, Meldola, Milan, Modena, Monza, Naples, Palermo, Pavia, Perugia, Pesaro, Pisa, Reggio Calabria, Reggio Emilia, Rimini, Rome, Turin, Udine
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
No phaseTaking people
This Study Aims to Improve the Stratification of Patients With Acute Myeloid Leukemia to Enable More Personalized and Effective Treatments, and to Identify and Functionally Validate, at the Single-cell Level, Biomarkers That Can Predict Response to Venetoclax.
Where
Milan
Age
18 years and over
People
420
Run by
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT07874100
Phase 3Taking people
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to customize therapy.
Where
Alexandria, Bari, Bologna, Brescia, Ferrara, Florence, Latina, Lecce, Novara, Padova, Palermo, Pavia, Perugia, Pescara, Piacenza, Ravenna, Reggio Calabria, Reggio Emilia, Rionero in Vulture (PZ), Rome, Salerno, Sassari, Siena, Tricase, Turin, Viterbo, Ospedale Valduce, ULSS3 SERENISSIMA - Ospedale dell'Angelo di Mestre
Age
18 years and over
People
172
Run by
Fondazione G.I.M.Em.A Franco Mandelli Ets
See details and how to joinNCT04174612 · EU 2023-505901-17-00
Phase 1/2Taking people
CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults
Where
Bergamo, Monza
Age
6 months to 75 years
People
18
Run by
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
See details and how to joinNCT07877610
Phase 3Taking people
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Where
Alexandria, Ascoli Piceno, Bergamo, Bologna, Brescia, Catania, Milan, Modena, Naples, Perugia, Ravenna, Rome, Rozzano, Siena, Trieste, Turin, Vicenza
Age
18 years and over
People
1,300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Bologna, Brescia, Genova, Milan, Monza, Naples, Pavia, Rome, Torino
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Bologna, Meldola, Milan, Rome, Vicenza
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1Taking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Monza, Rome
Age
0 years to 21 years
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Bologna, Florence, Milan, Novara, Ravenna, Rome, Turin
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 1Taking people
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Where
Rome
Age
6 months to 17 years
People
18 worldwide
Run by
AbbVie
See details and how to joinNCT07306832
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
Bologna, Busto Arsizio, Milan, Modena, Novara, Padova, Perugia, Pescara, Ravenna, Rimini, Rome
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
Phase 2Taking people
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER-81)
Where
Ancona, Bologna, Brescia, Lecce, Meldola, Ravenna, Rome, Rozzano, Turin
Age
18 years and over
People
191 worldwide
Run by
Ryvu Therapeutics S.A.
See details and how to join2023-505911-19-00 · EU 2023-505911-19-00
Phase 2Taking people
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Where
Ancona, Bologna, Brescia, Lecce, Meldola, Ravenna, Roma, Rozzano, Turin
Age
18 years and over
People
98 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06191263
Phase 2Enrolling by invitation
RVU120 Rollover Study
Where
Bari
Age
18 years and over
People
14 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00